Correlates and Risk Markers for Sleep Disturbance in Participants of the Autism Treatment Network / Jill A. HOLLWAY in Journal of Autism and Developmental Disorders, 43-12 (December 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-12 (December 2013) . - p.2830-2843 Titre : Correlates and Risk Markers for Sleep Disturbance in Participants of the Autism Treatment Network Type de document : Texte imprimé et/ou numérique Auteurs : Jill A. HOLLWAY, Auteur ; Michael G. AMAN, Auteur ; Eric BUTTER, Auteur Article en page(s) : p.2830-2843 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Sleep disturbance  Correlates  Risk markers Index. décimale : PER Périodiques Résumé : We explored possible cognitive, behavioral, emotional, and physiological risk markers for sleep disturbance in children with autism spectrum disorders. Data from 1,583 children in the Autism Treatment Network were analyzed. Approximately 45 potential predictors were analyzed using hierarchical regression modeling. As medication could confound findings, it was included in the analyses as a covariate. Results revealed that anxiety, autism symptom severity, sensory sensitivities, and GI problems were associated with sleep disturbance. IQ positively predicted sleep disturbance, and children with Asperger’s Disorder were more vulnerable than others. The amount of variance in sleep outcomes explained by predictor variables was modest (i.e., R 2 from .104 to .201). Predictor variables were evaluated in the context of a bidirectional theoretical framework. En ligne : http://dx.doi.org/10.1007/s10803-013-1830-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=218 [article] Correlates and Risk Markers for Sleep Disturbance in Participants of the Autism Treatment Network [Texte imprimé et/ou numérique] / Jill A. HOLLWAY, Auteur ; Michael G. AMAN, Auteur ; Eric BUTTER, Auteur . - p.2830-2843. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-12 (December 2013) . - p.2830-2843 Mots-clés : Autism spectrum disorder  Sleep disturbance  Correlates  Risk markers Index. décimale : PER Périodiques Résumé : We explored possible cognitive, behavioral, emotional, and physiological risk markers for sleep disturbance in children with autism spectrum disorders. Data from 1,583 children in the Autism Treatment Network were analyzed. Approximately 45 potential predictors were analyzed using hierarchical regression modeling. As medication could confound findings, it was included in the analyses as a covariate. Results revealed that anxiety, autism symptom severity, sensory sensitivities, and GI problems were associated with sleep disturbance. IQ positively predicted sleep disturbance, and children with Asperger’s Disorder were more vulnerable than others. The amount of variance in sleep outcomes explained by predictor variables was modest (i.e., R 2 from .104 to .201). Predictor variables were evaluated in the context of a bidirectional theoretical framework. En ligne : http://dx.doi.org/10.1007/s10803-013-1830-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=218

A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges / Laura SILVERMAN in Research in Autism Spectrum Disorders, 8-7 (July 2014)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 8-7 (July 2014) . - p.899-907 Titre : A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges Type de document : Texte imprimé et/ou numérique Auteurs : Laura SILVERMAN, Auteur ; Jill A. HOLLWAY, Auteur ; Tristram SMITH, Auteur ; Michael G. AMAN, Auteur ; L. Eugene ARNOLD, Auteur ; Xueliang PAN, Auteur ; Xiaobai LI, Auteur ; Benjamin L. HANDEN, Auteur Article en page(s) : p.899-907 Langues : Anglais (eng) Mots-clés : Atomoxetine (Strattera)  ADHD  Autism spectrum disorder  Drug trial  Parent training Index. décimale : PER Périodiques Résumé : Abstract Several randomized controlled trials (RCTs) involving children with autism spectrum disorder (ASD) have examined effectiveness of mono-therapies for problem behavior. However, results have not been as encouraging as in typically developing children. For example, when prescribed stimulants, children with ASD and hyperactivity/inattentiveness, show only moderately reduced symptoms, with frequent side effects. Therefore, alternative treatments or combinations of treatments are needed. The Children's Hyperactivity and Autism Research Treatment Study (CHARTS) is a randomized clinical trial comparing the individual and combined effects of atomoxetine and parent training to treat hyperactivity, inattentiveness, and noncompliance in children with ASD. Design challenges included the overall study design, targeting of different outcomes by different treatments, and data analysis. This article details options for addressing a number of these methodological issues in the context of conducting a large multicenter RCT with an ASD population. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233 [article] A multisite trial of atomoxetine and parent training in children with autism spectrum disorders: Rationale and design challenges [Texte imprimé et/ou numérique] / Laura SILVERMAN, Auteur ; Jill A. HOLLWAY, Auteur ; Tristram SMITH, Auteur ; Michael G. AMAN, Auteur ; L. Eugene ARNOLD, Auteur ; Xueliang PAN, Auteur ; Xiaobai LI, Auteur ; Benjamin L. HANDEN, Auteur . - p.899-907. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 8-7 (July 2014) . - p.899-907 Mots-clés : Atomoxetine (Strattera)  ADHD  Autism spectrum disorder  Drug trial  Parent training Index. décimale : PER Périodiques Résumé : Abstract Several randomized controlled trials (RCTs) involving children with autism spectrum disorder (ASD) have examined effectiveness of mono-therapies for problem behavior. However, results have not been as encouraging as in typically developing children. For example, when prescribed stimulants, children with ASD and hyperactivity/inattentiveness, show only moderately reduced symptoms, with frequent side effects. Therefore, alternative treatments or combinations of treatments are needed. The Children's Hyperactivity and Autism Research Treatment Study (CHARTS) is a randomized clinical trial comparing the individual and combined effects of atomoxetine and parent training to treat hyperactivity, inattentiveness, and noncompliance in children with ASD. Design challenges included the overall study design, targeting of different outcomes by different treatments, and data analysis. This article details options for addressing a number of these methodological issues in the context of conducting a large multicenter RCT with an ASD population. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233

---

1 (1 - 2 / 2)